150 results about "Type Vaccine" patented technology

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and / or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and / or circular mRNAs. The improved LNPs protect linear and / or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and / or therapeutic agents.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

Disclosed in the present invention are an HLA-A*11-targeted liver cancer mRNA vaccine, and a preparation method therefor and a use thereof. The mRNA vaccine of the present invention is an mRNA vaccine designed on the basis of the HLA-A*11:01 typing of a patient and having high-coverage and high-immunogenic tumor neoantigens, and is formed by transcribing DNA having a nucleotide sequence shown in SEQ ID NO: 32 to form an mRNA, and encapsulating the mRNA in lipid nanoparticles.

The invention discloses an mRNA (messenger ribonucleic acid) transcription skeleton vector and application thereof in preparation of a self-amplification type mRNA vaccine, and belongs to the technical field of veterinary biological products. According to the invention, alphavirus non-structural protein regions NSP2 and NSP3 of a self-amplification type mRNA skeleton are modified, a polyA tail is optimized, and a novel self-amplification type mRNA skeleton is constructed; the self-amplification type mRNA vaccine can improve the antigen expression efficiency, reduce the toxicity of non-structural protein to cells and improve the encapsulation efficiency and delivery efficiency by combining with the optimization of the components and proportion of a lipid nano delivery system, and meanwhile, the self-amplification type mRNA vaccine is wide in applicable pathogen antigen range and can be popularized to more animal epidemic diseases. The characteristics of high-efficiency expression, low-toxicity delivery and single-dose immunization are expected to renovate the immunization strategy of the existing animal vaccine, the epidemic prevention cost of the breeding industry is reduced, and the method has a wide industrial application prospect.

The invention discloses an ultralow-viscosity water-in-oil vaccine adjuvant and a preparation method thereof, and the ultralow-viscosity water-in-oil vaccine adjuvant comprises the following components in percentage by weight: 73%-75% of oil for injection, 20%-23% of a compound emulsifier, 2%-7% of a stabilizer, 0.5%-1.5% of a chiral immunomodulator and 1%-2% of a temperature-responsive material, the preparation method comprises the following steps: heating oil for injection as an oil phase; adding the compound emulsifier, the stabilizer, the chiral immunomodulator and the temperature response type material into the oil phase, stirring until the materials are completely dissolved to form a uniform oil phase mixture, slowly adding the water phase into the oil phase mixture, performing high-speed shearing to form primary emulsion, homogenizing the primary emulsion, and performing freeze drying to obtain the chiral immunomodulator. And carrying out emulsion refining by adopting a micro-fluidic technology to obtain the ultralow-viscosity water-in-oil type vaccine adjuvant. The ultra-low viscosity and injection comfort are achieved, precise immunization is achieved for different pathogens, multiple immune pathways are activated at the same time, a wide and lasting protection effect is generated by training an immune mechanism, and the ultra-low viscosity and injection comfort have the intelligent drug release characteristic, excellent stability and broad-spectrum applicability.

The invention provides a novel vaccine based on an adenovirus vector and application thereof. According to the present invention, the suitable monkey pox virus gene is selected for the first time, and is efficiently integrated with the chimpanzee virus vector (AdC68) to prepare the ideal virus vaccine, and the ideal virus vaccine is suitable for nasal cavity immunization and muscle immunization, and has good nasal cavity immunization effect. The novel monkey pox vaccine can be effectively used for prevention and control of monkey pox virus and vaccinia virus infection, and the two types of viruses are considered.

The invention discloses an NDRV [sigma] C circular RNA vaccine and application thereof, and belongs to the technical field of vaccines.Duck hepatitis A virus type 1 (DHAV-1) UTR and T4 bacteriophage I type intron self-splicing cyclization systems are adopted to construct circular RNA (CirRNA-[sigma] C) for expressing NDRV [sigma] C protein, and a vaccine preparation is prepared through a chitosan-polyethyleneimine (CS-PEI) nano delivery system. The feasibility of a circular RNA vaccine system based on DHAV-1UTR in poultry vaccines is confirmed for the first time, the established nano delivery technology and circular RNA vaccine platform have the characteristics of high stability, good safety, strong immunogenicity and the like, and an important technical path is provided for development of novel vaccines of NDRV and other viral epidemic diseases.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention discloses a multi-epitope peptide of novel coronavirus, a vaccine as well as a preparation method and application of the multi-epitope peptide, and belongs to the technical field of preparation of polypeptide vaccines. The multi-epitope peptide of the novel coronavirus not only contains T cell epitopes, but also contains B cell epitopes, and can induce humoral immunity and cellular immunity responses of an organism at the same time; the vaccine comprises epitopes from four antigenic proteins of novel coronavirus, and can induce comprehensive immune response. According to the multi-epitope peptide vaccine based on the novel coronavirus, the nano-carrier KFE8 serves as a delivery carrier, different antigen epitopes of the same pathogen or antigen epitopes of different pathogens can be presented in a mixed mode, safety is good, large-scale rapid preparation is achieved in an emergency state, and the vaccine is suitable for large-scale popularization and application. The coronavirus vaccine is a novel coronavirus universal vaccine which can cover various pathogen subtypes and induce broad-spectrum and long-term immune effects.

The invention belongs to the technical field of biological medicines, and particularly relates to an MAF vaccine as well as a preparation method and application thereof. In order to develop a nasal spray type vaccine capable of effectively preventing and treating fibrotic interstitial lung diseases and avoiding risk increase caused by local inflammatory reaction, the invention adopts two modes of taking a synthesized MAF protein as a model antigen, encapsulating the MAF protein by using a TLR7 adjuvant to form a peptide fragment vaccine or constructing an MAF adenovirus vaccine based on an adenovirus vector. Two vaccines based on the MAF target spot are successfully constructed. Animal experiment results prove that the two vaccines based on the MAF target spot have treatment and prevention effects on bleomycin-induced mouse pulmonary fibrosis models during nasal dripping immunization, and also have good safety in vivo. A good candidate vaccine is provided for future fibrotic disease prevention and treatment vaccine transformation research and clinical experiment development.

The invention relates to a method for detecting the in vitro relative potency of a type 9 HPV vaccine or antigen stock solution. Specifically, the in vitro relative potency of an HPV-VLP antigen stock solution and vaccine finished products (types 6, 11, 16, 18, 31, 33, 45, 52 and 58) is detected by using an enzyme-linked immunosorbent assay. The enzyme-linked immunosorbent assay has excellent accuracy and precision, the standardization level of HPV vaccine quality evaluation is improved, and a foundation is expected to be laid for promoting research and development of high-quality HPV vaccines.

The invention discloses an antigen LARP1 of cysticercus bovis and application of the antigen LARP1, and belongs to the technical field of biochemistry. The invention aims to provide a detection method and a treatment and prevention method for cysticercosis bovis. The invention provides an antigen of cysticercus bovis. The amino acid sequence of the antigen of cysticercus bovis is as shown in SEQ ID NO. 4. And a new candidate antigen is provided for research and development of novel vaccines, development of specific diagnostic reagents and the like.

The invention provides a herpes simplex virus mRNA vaccine as well as a preparation method and application thereof. According to the present invention, through a series of selection and optimization, the antigen protein suitable for preparing the mRNA vaccine, especially the combination of gD2 and gE1, is obtained, and the divalent vaccine prepared based on the antigen protein has excellent effect. The novel mRNA vaccine disclosed by the invention can efficiently induce humoral immune response, cellular immune response and T cell immune response, so that the novel mRNA vaccine can be effectively used for preventing and controlling herpes simplex virus infection, and can simultaneously cover the prevention and control of two viruses, namely HSV-1 and HSV-2.

This invention belongs to the field of biotechnology and relates to a specific monoclonal antibody against porcine circovirus type 2 (PCV2) Cap protein and its applications. The CDR of the heavy chain variable region of the monoclonal antibody includes CDR1, CDR2, and CDR3 as shown in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, respectively; the CDR of the light chain variable region of the monoclonal antibody includes CDR1, CDR2, and CDR3 as shown in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6, respectively. A sandwich ELISA method for protein content determination has been established, which is simple to operate, has good sensitivity and specificity, is widely applicable, and can perform high-throughput determination of multiple samples to detect the content of Cap protein, an effective antigen of various types of PCV2 vaccines, thus shortening the vaccine testing time.

The invention provides a novel vaccine adjuvant and application of the novel vaccine adjuvant in preparation of the vaccine adjuvant. The BCG-PSN and vaccine induced RBD specific IgG antibody and neutralizing antibody level are equivalent to those of an aluminum adjuvant, the BCG-PSN and vaccine induce Th1 biased T cell reaction, the induced T cell response level is obviously higher than that of the aluminum adjuvant, and K18-hACE2 mice are protected from being affected by Delta variant induced lung lesions. As a vaccine adjuvant, BCG-PSN has wide compatibility and safety, and has no toxic or side effect.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The application discloses a temperature-uniform vaccine rewarming device, which belongs to the technical field of vaccine rewarming devices. The device comprises a shell, an electric heating wire arranged in the shell, a sealing cover threadedly connected to the upper side of the shell, a support disc sealingly and slidably connected to the shell, a water bath cavity formed by the shell and the support disc, water bath liquid stored in the water bath cavity, a support ring annularly arranged on the support disc, symmetrical connecting rods fixed to the lower side of the support ring, and an extrusion disc jointly and limitingly connected to the connecting rods symmetrically arranged on the same support ring. The connecting rod on one side is sealingly and slidably connected to a first extrusion cylinder fixed to the adjacent extrusion disc, and an annular air bag is fixed to the support ring. The annular air bag is inflated to separate the water bath liquid from the bottleneck of the vaccine, so that the water bath liquid is prevented from splashing into the bottle mouth of the vaccine during movement, and the probability of the vaccine being contaminated is reduced.

The invention provides preparation of a novel mRNA vaccine and application of the novel mRNA vaccine in a medicine composition for treating hepatitis B virus diseases. Specifically, the invention provides a chronic hepatitis B infection therapeutic mRNA vaccine, which comprises mRNA for coding a large protein (L protein) region of hepatitis B virus surface antigen, and simultaneously comprises two mRNA for respectively coding a middle protein (M protein) region of hepatitis B virus surface antigen and a small protein (S protein) region, or comprises mRNA for coding the small protein (S protein) region. The mRNA therapeutic vaccine provided by the invention can break the immune tolerance state in chronic hepatitis B infection, and has the potential of functionally curing chronic hepatitis B infection clinically.

The present invention discloses a method for preparing a metal organic framework-based Pickering emulsion vaccine and its application, comprising the following steps: using Al(NO3)3·9H2O and 4,4'-diphenyldicarboxylic acid as raw materials, obtaining white DUT-5 powder by a solvothermal method; adding the prepared DUT-5 to ultrapure water, and mixing by simple ultrasound to obtain a Pickering emulsion; mixing the obtained Pickering emulsion with PCV2Cap protein and placing it in a shaking table overnight; ultrafiltration and centrifugation of the obtained mixed emulsion to obtain DUT-5-PE@CAP. The vaccine of the present invention can effectively deliver antibodies or proteins to specific locations and stimulate a strong immune response, providing new possibilities for the development of new vaccines, and providing a new method for the prevention and treatment of porcine circovirus type II, which is of great significance for controlling the disease.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

The invention relates to the technical field of mRNA vaccine preparation, and particularly discloses a porcine epidemic diarrhea virus mRNA vaccine and a preparation method thereof. The mRNA vaccine is prepared by adopting cow milk source exosome as a carrier and wrapping mRNA encoding PEDV-S protein in the carrier through an ultrasonic loading method. According to the preparation method, the encapsulation efficiency of mRNA and the stability of the vaccine are remarkably improved, the prepared vaccine can more efficiently promote antigen expression, stronger cellular immunity and humoral immunity are induced in a mouse body, and a safe and efficient novel vaccine candidate is provided for preventing and controlling porcine epidemic diarrhea.

The invention discloses a cGAS-STING pathway activated tumor vaccine based on X-type framework nucleic acid, and belongs to the technical field of biological medicine and immune engineering. The vaccine is composed of X-type framework nucleic acid and alkynyl modified antigen peptide, the X-type framework nucleic acid is of a four-arm Halide knot structure formed by self-assembly of four oligonucleotide chains, and the antigen peptide is coupled to the oligonucleotide chains. According to the invention, the unique multi-branch topological structure of the X-type framework nucleic acid is utilized to enhance the binding stability with cGAS and efficiently activate a cGAS-STING signal channel without additional adjuvants; meanwhile, stable presentation and efficient delivery of the antigen peptide are realized, dendritic cell maturation and antigen presentation are promoted, and strong antigen specific CD8 + T cell immune response is induced. The vaccine shows a remarkable tumor inhibition effect in tumor prevention and treatment models, has the advantages of stable structure, high immunization efficiency, good safety and the like, and provides a novel vaccine platform for tumor immunotherapy.

The application discloses a SARS-CoV-2 epitope type vaccine multi-epitope combination and application, and belongs to the technical field of coronavirus vaccine research and development.The first aspect of the application relates to a fusion protein, which comprises in sequence: (a) a SARS-CoV-2 spike protein receptor binding domain or a functional fragment thereof; (b) a T cell epitope domain, comprising: a CTL epitope cluster, the CTL epitope cluster comprising at least one CD8+ T cell epitope polypeptide selected from SEQ ID NO: 1-15; and (c) an immunoglobulin Fc domain.The application adopts a tandem strategy of immunodominant epitopes + conserved epitopes, predicts high-affinity T cell epitopes by computational biology methods, evaluates the HLA restriction in different populations, introduces a flexible linker peptide for optimization design, evaluates the immune effect difference of different combinations through in vitro and animal models, analyzes the synergistic or competitive relationship between epitopes, and optimizes the vaccine design.Through systematic comparison of the immunological effect difference of different epitope combinations and the adaptability to various vaccine platforms, the application establishes an optimized safe, efficient, broad-spectrum and long-acting multi-epitope vaccine design strategy, and has significant application value and important transformation value.

The invention provides a coxsackie virus group B type 2 strain and application thereof, and relates to the technical field of biological medicine. The strain is named as KM31-C05, and is preserved in the China Center for Type Culture Collection on May 16, 2025, the preservation number is CCTCC NO: V202541, and the preservation address is Wuhan University, Wuhan, China. The virus strain is a human coxsackie virus group B type 2 wild type single purified virus strain, and the virus strain is high in virus replication capacity and good in hereditary stability and immunogenicity; the virus strain can be applied to development of a production virus seed of a human coxsackie virus group B type 2 vaccine, and is suitable for development of an attenuated coxsackie virus group B type 2 vaccine and an inactivated coxsackie virus group B type 2 vaccine; the method is used for CVB2 infection and pathogenic mechanism research, CVB2 vaccine evaluation and antiviral drug screening.

The utility model relates to the technical field of vaccine bottle drying devices, in particular to a multi-station cooperative type vaccine bottle surface quick drying device which comprises a rack, a stock bin and a sorting bin, a vibration mechanism is further arranged on the rack, and the stock bin and the sorting bin are located above the vibration mechanism. A discharging channel extending outwards is arranged on the side, close to the feeding end of the sequencing bin, of the stock bin, and a plurality of flow guide grooves are formed in a bottom plate of the sequencing bin. A blow-drying machine is further arranged above the stock bin, an air outlet of the blow-drying machine faces the stock bin, and air flows from the stock bin to the sorting bin through the discharging channel. According to the utility model, the blow-drying machine blows a large area of air above the stock bin, so that a plurality of vaccine bottles are primarily blown; under the action of continuous vibration and stirring of the vaccine bottles, air can make contact with all faces of the vaccine bottles, and the air enters the sorting bin under the guidance of the discharging channel to conduct secondary blowing on the vaccine bottles arranged in the flow guide groove in order; no extra workload needs to be added in the whole process, and the production efficiency is greatly improved.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

The present invention discloses a monoclonal antibody against porcine SLFN11 protein and its application, relating to the field of biotechnology. The monoclonal antibody against porcine SLFN11 protein comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO.1 and a light chain variable region with the amino acid sequence shown in SEQ ID NO.3. The monoclonal antibody has an IgG1 heavy chain constant region and a kappa light chain constant region, exhibiting strong affinity and stability and capable of specifically binding to porcine SLFN11 protein. This invention provides an excellent immunological tool for further exploring the antiviral function and mechanism of the SLFN11 protein, laying the foundation for the development of genetically engineered antibody drugs and novel vaccines for the prevention or treatment of porcine viral diseases.

This invention provides a virus-like particle vaccine gE-eVLP for varicella-zoster virus, a recombinant adenovirus vector vaccine, an mRNA vaccine, and their preparation methods and applications, belonging to the field of vaccine technology. The nucleotide sequence of the virus-like particle vaccine gE-eVLP provided by this invention includes a signal peptide sequence, a truncated and / or mutated sequence of the gE domain without the original signal peptide, and an EGE motif; the recombinant adenovirus vector vaccine and mRNA vaccine contain gE-eVLP. This invention innovatively integrates EABR self-assembled particle technology into the VZV adenovirus vector vaccine and mRNA vaccine technology platform, and systematically evaluates the immunogenicity of three novel vaccines: Ad26-tPA-gE-eVLP, AdC68-tPA-gE-eVLP, and LNP-tPA-gE-eVLP, providing important experimental evidence for the development of a new generation of highly effective and safe VZV vaccines.